JP2019532616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532616A5 JP2019532616A5 JP2018563544A JP2018563544A JP2019532616A5 JP 2019532616 A5 JP2019532616 A5 JP 2019532616A5 JP 2018563544 A JP2018563544 A JP 2018563544A JP 2018563544 A JP2018563544 A JP 2018563544A JP 2019532616 A5 JP2019532616 A5 JP 2019532616A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide sequence
- fusion protein
- sequence
- nucleic acid
- rdcvf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 49
- 108020001507 fusion proteins Proteins 0.000 claims 32
- 102000037865 fusion proteins Human genes 0.000 claims 32
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 12
- 239000013604 expression vector Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000608 photoreceptor cell Anatomy 0.000 claims 2
- 239000003223 protective agent Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000013607 AAV vector Substances 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008096 Cerebral atrophy Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010010541 Congenital melanosis Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 101000597433 Mus musculus Nucleoredoxin-like protein 1 Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406552P | 2016-10-11 | 2016-10-11 | |
| US62/406,552 | 2016-10-11 | ||
| PCT/US2017/056030 WO2018071465A1 (en) | 2016-10-11 | 2017-10-11 | Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532616A JP2019532616A (ja) | 2019-11-14 |
| JP2019532616A5 true JP2019532616A5 (enExample) | 2020-11-19 |
| JP7028802B2 JP7028802B2 (ja) | 2022-03-02 |
Family
ID=61906325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563544A Active JP7028802B2 (ja) | 2016-10-11 | 2017-10-11 | 短鎖型桿体由来錐体生存因子及び親水性ペプチド間の融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10946063B2 (enExample) |
| EP (1) | EP3526238A4 (enExample) |
| JP (1) | JP7028802B2 (enExample) |
| KR (2) | KR20190058388A (enExample) |
| CN (1) | CN109415423A (enExample) |
| AU (1) | AU2017344059B2 (enExample) |
| BR (1) | BR112018076674A2 (enExample) |
| CA (1) | CA3025977A1 (enExample) |
| IL (1) | IL263990A (enExample) |
| MX (1) | MX2018015596A (enExample) |
| NZ (1) | NZ748634A (enExample) |
| WO (1) | WO2018071465A1 (enExample) |
| ZA (1) | ZA201808041B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110819647A (zh) * | 2018-08-07 | 2020-02-21 | 康码（上海）生物科技有限公司 | 信号肽相关序列及其在蛋白质合成中的应用 |
| US20230146121A1 (en) * | 2019-12-09 | 2023-05-11 | Chigenovo Co., Ltd. | Use of cyp4v2 and rdcvf in the manufacture of medicament |
| CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院（北京大学第三临床医学院） | 一种分离的核酸分子及其用途 |
| US20240342313A1 (en) * | 2023-03-30 | 2024-10-17 | Pharma Cinq, Llc | Vector encoding rod-derived cone viability factor and human igk signal sequence |
| US20260091133A1 (en) * | 2024-09-27 | 2026-04-02 | Pharma Cinq, Llc | Rod-derived cone viability factor fusion protein |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07241196A (ja) * | 1994-03-04 | 1995-09-19 | Teruhiko Beppu | アルブミンおよびヒトアポリポプロテインｅ様遺伝子を有する融合遺伝子、それを挿入したプラスミド並びにその用途 |
| WO1998024922A1 (en) | 1996-12-02 | 1998-06-11 | Valentis, Inc. | Insulin-like growth factor i (igf-i) expression system and methods of use |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| FR2870241B1 (fr) | 2004-05-13 | 2015-02-27 | Novartis Ag | Facteur de viabilite des cones derive des batonnets ou rdcvf et applications |
| EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
| EP2281047B1 (en) * | 2008-04-15 | 2020-04-08 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (rdcvf) |
| JP5748223B2 (ja) | 2008-09-10 | 2015-07-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子およびその使用 |
| JPWO2010050586A1 (ja) | 2008-10-31 | 2012-03-29 | ディナベック株式会社 | 組み換え蛋白質の発現を増強する方法 |
| WO2012140676A2 (en) | 2011-04-12 | 2012-10-18 | Appaiah C B | Chimeric antibacterial polypeptides |
| BR112014010091B1 (pt) * | 2011-10-27 | 2022-11-08 | Wellstat Ophthalmics Corporation | Ácido nucleico, vetor viral, preparação farmacêutica, uso destes, método para produção de uma proteína rdcvf, e método in vitro ou ex vivo de secreção de uma proteína rdcvf a partir de uma célula |
| AU2013289881B2 (en) * | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
| RU2723101C2 (ru) | 2013-12-06 | 2020-06-08 | Инсерм (Инститьют Насьонал Де Ла Санте Ет Де Ла Решерш Медикаль) | Вектор, способ лечения хороидермии, способ селективной экспрессии полинуклеотида |
| US10857240B2 (en) | 2016-01-05 | 2020-12-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
-
2017
- 2017-10-11 BR BR112018076674-7A patent/BR112018076674A2/pt unknown
- 2017-10-11 JP JP2018563544A patent/JP7028802B2/ja active Active
- 2017-10-11 MX MX2018015596A patent/MX2018015596A/es unknown
- 2017-10-11 EP EP17860101.9A patent/EP3526238A4/en active Pending
- 2017-10-11 KR KR1020187037891A patent/KR20190058388A/ko not_active Ceased
- 2017-10-11 KR KR1020237037858A patent/KR20230156440A/ko active Pending
- 2017-10-11 CN CN201780040158.3A patent/CN109415423A/zh active Pending
- 2017-10-11 CA CA3025977A patent/CA3025977A1/en active Pending
- 2017-10-11 AU AU2017344059A patent/AU2017344059B2/en active Active
- 2017-10-11 NZ NZ748634A patent/NZ748634A/en unknown
- 2017-10-11 WO PCT/US2017/056030 patent/WO2018071465A1/en not_active Ceased
- 2017-10-11 US US16/301,764 patent/US10946063B2/en active Active
-
2018
- 2018-11-28 ZA ZA2018/08041A patent/ZA201808041B/en unknown
- 2018-12-27 IL IL263990A patent/IL263990A/en unknown
-
2021
- 2021-02-10 US US17/172,202 patent/US12076367B2/en active Active
-
2024
- 2024-07-26 US US18/785,213 patent/US20240374683A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108350467B (zh) | 基因构建体 | |
| JP6268164B2 (ja) | Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法 | |
| JP2021502813A5 (enExample) | ||
| TW202106699A (zh) | 用於玻璃體內遞送之變異體aav蛋白殼 | |
| JP2019537437A5 (enExample) | ||
| CN105980569A (zh) | 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法 | |
| MX2010012592A (es) | Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas. | |
| RU2014121256A (ru) | Векторы, кодирующие фактор жизнеспособности колбочек, полученный из палочек | |
| JP7289306B2 (ja) | 網膜障害を治療するための組成物及び方法 | |
| US20240335562A1 (en) | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders | |
| CN102282165A (zh) | Gdnf剪接变体及其用途 | |
| JP2021511030A5 (enExample) | ||
| CN111405908A (zh) | Tau肽免疫原构建体 | |
| WO2018043707A1 (ja) | 視覚機能再生剤又は視覚機能低下予防剤 | |
| JP2023533601A (ja) | タンパク質凝集物を溶解するための組成物および方法 | |
| TW202509227A (zh) | 用於治療與cdkl5缺乏相關之病症之組合物及方法 | |
| KR20230093400A (ko) | Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물 | |
| JP7028802B2 (ja) | 短鎖型桿体由来錐体生存因子及び親水性ペプチド間の融合タンパク質 | |
| JP2024534667A (ja) | 神経系疾患の直接分化転換治療 | |
| US10017554B2 (en) | Neuropeptide Y-derived peptides | |
| CN118791624B (zh) | 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白 | |
| Liu et al. | Ocular drug delivery: molecules, cells, and genes | |
| US20240216537A1 (en) | Gene therapy for neuroprotection | |
| WO2021184009A1 (en) | Kir 7.1 gene therapy vectors and methods of using the same | |
| CN121969760A (zh) | 用于表达治疗剂的组合物和方法 |